Metsera (MTSR) Competitors $31.14 +0.84 (+2.77%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTSR vs. ASND, RDY, VTRS, QGEN, MRNA, VRNA, BBIO, BPMC, ELAN, and ROIVShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Its Competitors Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Qiagen Moderna Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Elanco Animal Health Roivant Sciences Metsera (NASDAQ:MTSR) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment. Which has higher valuation and earnings, MTSR or ASND? Metsera has higher earnings, but lower revenue than Ascendis Pharma A/S. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetseraN/AN/A-$209.13MN/AN/AAscendis Pharma A/S$490.75M24.71-$409.12M-$5.16-38.43 Does the media favor MTSR or ASND? In the previous week, Ascendis Pharma A/S had 25 more articles in the media than Metsera. MarketBeat recorded 26 mentions for Ascendis Pharma A/S and 1 mentions for Metsera. Metsera's average media sentiment score of 1.87 beat Ascendis Pharma A/S's score of 0.83 indicating that Metsera is being referred to more favorably in the media. Company Overall Sentiment Metsera Very Positive Ascendis Pharma A/S Positive Do analysts prefer MTSR or ASND? Metsera presently has a consensus target price of $55.00, indicating a potential upside of 76.62%. Ascendis Pharma A/S has a consensus target price of $242.93, indicating a potential upside of 22.49%. Given Metsera's higher possible upside, equities analysts clearly believe Metsera is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metsera 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MTSR or ASND more profitable? Metsera has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Company Net Margins Return on Equity Return on Assets MetseraN/A N/A N/A Ascendis Pharma A/S -54.94%N/A -24.31% SummaryMetsera beats Ascendis Pharma A/S on 5 of the 8 factors compared between the two stocks. Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.18B$3.11B$5.63B$9.83BDividend YieldN/A2.23%3.79%4.08%P/E RatioN/A7.0921.9023.75Price / SalesN/A367.51465.67116.64Price / CashN/A42.3037.4059.05Price / Book7.288.659.096.18Net Income-$209.13M-$54.65M$3.25B$264.89M7 Day Performance2.43%6.59%4.76%2.66%1 Month Performance-27.55%9.57%6.72%3.05%1 Year PerformanceN/A14.06%30.51%25.05% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$31.14+2.8%$55.00+76.6%N/A$3.18BN/A0.0081Positive NewsGap UpASNDAscendis Pharma A/S2.4118 of 5 stars$191.49+0.6%$239.80+25.2%+37.5%$11.64B$393.54M-37.111,017High Trading VolumeRDYDr. Reddy's Laboratories2.925 of 5 stars$13.82+1.6%$16.95+22.7%-13.3%$11.35B$3.81B20.9327,811News CoverageAnalyst RevisionVTRSViatris2.0499 of 5 stars$9.70+3.3%$10.40+7.2%-6.2%$11.02B$14.74B-3.3432,000Insider TradeHigh Trading VolumeQGENQiagen3.4018 of 5 stars$48.02-0.7%$49.69+3.5%+9.4%$10.75B$1.98B28.375,765News CoverageMRNAModerna4.3935 of 5 stars$26.12-1.8%$43.59+66.9%-67.6%$10.35B$3.24B-3.475,800VRNAVerona Pharma PLC American Depositary Share2.3682 of 5 stars$105.28-0.1%$109.00+3.5%+285.5%$8.97B$42.28M-106.3430Short Interest ↓BBIOBridgeBio Pharma4.3671 of 5 stars$46.58+1.4%$61.35+31.7%+111.1%$8.78B$221.90M-11.39400Insider TradeGap DownBPMCBlueprint MedicinesN/A$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ELANElanco Animal Health2.8826 of 5 stars$16.61+0.8%$16.33-1.7%+27.8%$8.18B$4.44B19.319,000News CoveragePositive NewsROIVRoivant Sciences2.9237 of 5 stars$11.49-0.5%$16.50+43.6%+2.8%$7.85B$29.05M-45.96860Gap Down Related Companies and Tools Related Companies ASND Alternatives RDY Alternatives VTRS Alternatives QGEN Alternatives MRNA Alternatives VRNA Alternatives BBIO Alternatives BPMC Alternatives ELAN Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access